Do GLP-1 Telehealth Providers Use Real Doctors? NP vs. MD Explained

When you sign up for a GLP-1 telehealth platform, who actually writes your prescription? Is it a board-certified physician, a nurse practitioner, a physician assistant — or someone else entirely? The answer varies significantly by platform, and it matters more than most patients realize.

The Three Types of Prescribers

Physicians (MD or DO) complete medical school (4 years) plus residency training (3–7 years depending on specialty). They have the most extensive clinical training and can prescribe independently in all 50 states. Board-certified physicians in obesity medicine, endocrinology, or internal medicine have the most relevant training for GLP-1 prescribing.

Nurse Practitioners (NP) complete a master's or doctoral nursing program after a bachelor's in nursing. Their prescribing authority depends on state law — as of 2026, approximately 26 states grant NPs "full practice authority," meaning they can prescribe independently without physician oversight. In the remaining states, NPs must operate under a collaborative practice agreement with a physician who reviews charts, often monthly.

Physician Assistants (PA) complete a master's-level PA program (typically 2–3 years) and practice under physician supervision in all states, though the degree of required supervision varies. PAs can prescribe GLP-1 medications in every state, but always with some form of physician relationship documented.

How Telehealth Platforms Actually Staff

A STAT investigation in 2024 found that a handful of medical groups — Management Services Organizations (MSOs) — provide prescribers to dozens of telehealth websites simultaneously. These MSOs maintain networks of licensed clinicians across all 50 states, allowing telehealth platforms to launch quickly by "renting" clinical services rather than hiring prescribers directly.

This model is not inherently problematic — the question is whether the prescribers have adequate time, training, and support to provide quality care. A physician seeing 8 GLP-1 patients per hour on a high-volume platform is operating differently than a physician seeing 2 per hour with comprehensive clinical review.

The ratio matters. Some platforms use predominantly NPs and PAs with physician oversight, which keeps costs lower but may mean the prescriber has less clinical training in obesity medicine specifically. Others employ or contract directly with physicians who specialize in weight management. Neither model is automatically better — what matters is the clinical protocol, time allocated per patient, and quality of oversight.

Questions to Ask Your Platform

Before enrolling, ask these questions directly — either through the platform's chat/email or during your first consultation:

"What are the credentials of the provider who will manage my care?" You're looking for the specific type (MD, DO, NP, PA) and ideally whether they have specialty training or certification in obesity medicine, endocrinology, or internal medicine.

"Will I see the same provider at each follow-up, or does it rotate?" Continuity of care matters for medication management. If you see a different provider every visit, your clinical history gets lost in the shuffle.

"How many patients does each provider manage?" This is a proxy for how much attention you'll get. A provider managing 2,000 active GLP-1 patients is spread thinner than one managing 200.

"If I have an urgent question about side effects, who responds and how quickly?" Some platforms have 24/7 clinical messaging. Others route side-effect questions through a customer service team with no medical training.

The Dosing Error Problem

Inadequate prescriber oversight has real consequences. KFF Health News documented a case where a telehealth patient was prescribed 2.21 mg of semaglutide as a starting dose — nearly nine times the recommended initial dose of 0.25 mg. The patient experienced elevated heart rate and vision problems lasting weeks. When she tried to reach her prescriber, she was directed to a "care team" customer service representative instead.

This type of error is not unique to telehealth — prescribing mistakes happen in in-person settings too. But the risk is amplified when platforms optimize for speed and volume over clinical thoroughness. A platform that processes hundreds of new patients daily with minimal prescriber involvement is more likely to produce dosing errors than one that allocates adequate clinical time per patient.

What "Good" Looks Like

The best GLP-1 telehealth platforms share specific information about their clinical model: who prescribes, what their qualifications are, how consultations are structured, and what oversight exists. Transparency about the clinical team is a positive signal. Opacity about it is not.